These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34862871)

  • 1. Study on the clinical effects of targeted therapy on elderly patients with gastric cancer.
    Gao L; Li W; Liu Y; Zhang C; Gao W; Wang L
    Pak J Pharm Sci; 2021 Sep; 34(5(Special)):2041-2045. PubMed ID: 34862871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apatinib for the treatment of gastric cancer.
    Roviello G; Ravelli A; Fiaschi AI; Cappelletti MR; Gobbi A; Senti C; Zanotti L; Polom K; Reynolds AR; Fox SB; Generali D
    Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):887-92. PubMed ID: 27376400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression-free survival with regorafenib in gastric cancer.
    Burki TK
    Lancet Oncol; 2016 Aug; 17(8):e323. PubMed ID: 27375105
    [No Abstract]   [Full Text] [Related]  

  • 4. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
    Roviello G; Ravelli A; Polom K; Petrioli R; Marano L; Marrelli D; Roviello F; Generali D
    Cancer Lett; 2016 Mar; 372(2):187-91. PubMed ID: 26797419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apatinib for the treatment of gastric cancer.
    Geng R; Li J
    Expert Opin Pharmacother; 2015 Jan; 16(1):117-22. PubMed ID: 25420417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
    Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials.
    Shan F; Miao R; Xue K; Li Z; Li Z; Bu Z; Wu A; Zhang L; Wu X; Zong X; Wang X; Li S; Ji X; Jia Z; Li Z; Ji J
    Cancer Lett; 2016 Oct; 380(2):598-607. PubMed ID: 26724681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of endostatin combined with continuous transcatheter arterial infusion and chemoembolization on gastric cancer with liver metastasis and analysis of prognosis.
    Chen L; Shi H; Che Y; Sun W; Niu X; Lu W
    J BUON; 2020; 25(3):1469-1475. PubMed ID: 32862592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model.
    Jin Y; Wei L; Jiang Q; Song X; Teng C; Fan C; Lv Y; Liu Y; Shen W; Li L; Huang D; Xin T
    Sci Rep; 2018 Oct; 8(1):15837. PubMed ID: 30367145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targeting to treat gastric cancer.
    Aoyagi K; Kouhuji K; Kizaki J; Isobe T; Hashimoto K; Shirouzu K
    World J Gastroenterol; 2014 Oct; 20(38):13741-55. PubMed ID: 25320512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apatinib for molecular targeted therapy in tumor.
    Zhang H
    Drug Des Devel Ther; 2015; 9():6075-81. PubMed ID: 26622168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor a inhibition in gastric cancer.
    Park DJ; Thomas NJ; Yoon C; Yoon SS
    Gastric Cancer; 2015 Jan; 18(1):33-42. PubMed ID: 24993497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.
    Roviello G; Petrioli R; Marano L; Polom K; Marrelli D; Perrella A; Roviello F
    Gastric Cancer; 2016 Jan; 19(1):31-41. PubMed ID: 26329368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
    Lee EQ; Muzikansky A; Duda DG; Gaffey S; Dietrich J; Nayak L; Chukwueke UN; Beroukhim R; Doherty L; Laub CK; LaFrankie D; Fontana B; Stefanik J; Ruland S; Caruso V; Bruno J; Ligon K; Reardon DA; Wen PY
    Cancer Med; 2019 Oct; 8(13):5988-5994. PubMed ID: 31444999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antiangiogenic drugs enhance the ability of invasion and metastasis of breast cancer cells under serum starvation and hypoxia].
    Wei L; Cuicui Z; Jing W; Kai L
    Zhonghua Zhong Liu Za Zhi; 2015 Apr; 37(4):244-50. PubMed ID: 26462887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis and apatinib: a new hope for patients with advanced gastric cancer?
    de Mello RA; de Oliveira J; Antoniou G
    Future Oncol; 2017 Feb; 13(4):295-298. PubMed ID: 27928929
    [No Abstract]   [Full Text] [Related]  

  • 17. Current advances in targeted therapies for metastatic gastric cancer: improving patient care.
    Aguiar PN; Muniz TP; Miranda RR; Tadokoro H; Forones NM; Monteiro ID; Castelo-Branco P; Janjigian YY; De Mello RA
    Future Oncol; 2016 Mar; 12(6):839-54. PubMed ID: 26838766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
    Wu Q; Fu Y; Wen W; Xi T; Zhao G
    J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical observation and therapeutic evaluation of Rh-endostatin combined with DP regimen in treating patients with advanced esophageal cancer.
    Deng WY; Song T; Li N; Luo SX; Li X
    Asian Pac J Cancer Prev; 2014; 15(16):6565-70. PubMed ID: 25169488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting receptor tyrosine kinases in gastric cancer.
    Morishita A; Gong J; Masaki T
    World J Gastroenterol; 2014 Apr; 20(16):4536-45. PubMed ID: 24782606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.